Patients with hilar and extrahepatic cholangiocarcinoma (CCA) had longer median overall survival times when treated at academic/research programs compared to other facilities, according to data presented at the 2022 American Society of Clinical Oncology Annual Meeting.
The median overall survival for patients with CCA treated at academic/research programs was roughly 14 months (95% CI, 14.1-14.8 months). This was significantly longer (P <.001) than patients treated at integrated network cancer programs (9.7 months; 95% CI, 9.3-10.2 months), comprehensive community cancer programs (8.7 months; 95% CI, 8.4-8.9 months), and community cancer programs (6.9 months; 95% CI, 6.4-7.7 months).
The overall median survival of all patients included in the study was 11.2 months. In specific types of CCA, patients with Klatskin tumors had a median survival of 10.3 months when treated at an academic/research program compared to only 3.6 months for patients treated at a community cancer program (P <.0010).
Read more about CCA prognosis
Patients with mucinous adenocarcinomas also had a significantly higher survival of 26.5 months when treated in an academic/research program compared to 16.2 months in a comprehensive community center program (P <.001). No difference in survival time was observed between different treatment facilities for patients with papillary adenocarcinomas, however.
“Further studies are needed to ascertain why academic/research programs have superior outcomes in these patients,” the authors said.
A total of 57,146 patients with hilar and extrahepatic CCA were identified for the study using ICD-O-3 histology codes from the National Cancer Database between 2004 and 2017. The patient data were segmented into 4 different facility types: academic/research programs, community cancer programs, comprehensive community cancer programs, and integrated network cancer programs. The data were analyzed and Kaplan Meier curves were computed using SPSS to measure survival times.
Abodunrin F, Eyitemi J, Jain S, et al. Survival trends in hilar and extrahepatic cholangiocarcinoma based on facility type: a National Cancer Database analysis. J Clin Oncol. 2022;40(16):e13536. doi:10.1200/JCO.2022.40.16_suppl.e13536